MergerAug 6, 2026, 04:04 PM
NextCure to Merge with Avere Therapeutics; Avere Secures $320M Financing
AI Summary
NextCure, Inc. announced a proposed merger with Avere Therapeutics in an all-stock transaction, with Avere securing approximately $320 million in gross proceeds from a concurrent private financing. The combined company will operate as Avere Therapeutics and trade under "AVRX" on Nasdaq, with NextCure stockholders receiving contingent value rights for legacy assets. The company also reported Q2 2026 financial results, including a net loss of $14.9 million and cash of $20.1 million, alongside ongoing restructuring efforts and the continuation of the LNCB74 program by LigaChem Biosciences.
Key Highlights
- NextCure announced a definitive merger agreement with Avere Therapeutics in an all-stock transaction.
- Avere Therapeutics secured approximately $320 million in gross proceeds from a concurrent private financing.
- Existing NextCure stockholders are expected to receive contingent value rights (CVRs) for legacy assets.
- LigaChem Biosciences will continue LNCB74 development; NextCure eligible for future milestones and royalties.
- Cash, cash equivalents, and marketable securities were $20.1 million as of June 30, 2026.
- Net loss for Q2 2026 was $14.9 million, a decrease from $26.8 million in Q2 2025.
- Research and development expenses decreased to $7.4 million in Q2 2026 from $24.1 million in Q2 2025.
- Asset impairment costs totaled $5.1 million in Q2 2026 due to restructuring initiatives.
Price Impact
More from NXTC